Benefits of Vitamin K2 (MK-7)

Evidence-Based Benefits

• Bone health — a 2013 RCT by Knapen et al. (n=244 postmenopausal women) found MK-7 at 180 mcg/day for 3 years significantly reduced age-related bone loss at the lumbar spine and femoral neck, and improved bone strength indices
• Cardiovascular protection — K2 activates matrix Gla protein (MGP), the most potent known inhibitor of vascular calcification; the Rotterdam Study (2004, n=4,807) found high dietary K2 intake was associated with 52% lower risk of severe aortic calcification and 57% lower cardiovascular mortality over 10 years
• Synergy with vitamin D3 — vitamin D increases calcium absorption, while K2 ensures that calcium is deposited in bones rather than accumulating in arteries; this combination may reduce the cardiovascular risk sometimes associated with calcium supplementation
• Dental health — osteocalcin activation by K2 supports dentin mineralization and may reduce cavity formation; K2-dependent proteins are expressed in dental tissues

What the Research Says

Vitamin K2 (MK-7) is emerging as a significant factor in bone and cardiovascular health. A 3-year randomized controlled trial by Knapen et al. (2013) involving 244 postmenopausal women demonstrated that MK-7 supplementation at 180 mcg/day effectively reduced bone mineral density decline at the lumbar spine and femoral neck, highlighting its role in preserving bone health. Additionally, a randomized crossover study by Schurgers et al. (2007) with 23 participants found that MK-7 has a longer half-life compared to vitamin K1, leading to more efficient osteocalcin carboxylation, which is crucial for bone formation.

In the context of cardiovascular health, the Rotterdam Study by Geleijnse et al. (2004), involving 4,807 participants, revealed that higher dietary intake of menaquinone was associated with a reduced risk of coronary heart disease and aortic calcification. This study underscored the importance of MK-7 over K1 in cardiovascular protection. Mechanistically, MK-7 activates osteocalcin, promoting bone formation, and MGP (matrix Gla protein), which inhibits vascular calcification, providing a dual benefit for both skeletal and cardiovascular systems.

Despite these findings, there remains a need for larger-scale randomized controlled trials to further validate the cardiovascular benefits of MK-7 and to explore its potential interactions with anticoagulant therapies at higher doses.

Related Conditions